Paper
Pharmacotherapy for gastric and intestinal cramping pain: current and emerging therapies
Published Oct 3, 2023 · Taraneh Mousavi, Mohammad Abdollahi, Mohammadhossein Sharifnia
Expert Opinion on Pharmacotherapy
1
Citations
0
Influential Citations
Abstract
ABSTRACT Introduction Acute gastrointestinal cramping pain (GICP) is a debilitating condition that affects many people worldwide, significantly reducing their quality of life. As such, prompt treatment is crucial. Areas covered This article will explore relevant literature from databases such as PubMed, Scopus, Google Scholar, Cochrane Library, and Web of Science. Additionally, we searched ClinicalTrials.gov and the WHO ICTRP database for the latest clinical trials. Expert opinion Consensus dictates that antispasmodics such as hyoscine-N-butyl bromide and mebeverine should be the primary treatment for GICP. If these prove ineffective, patients can switch to an antispasmodic with a different mode of action or add acetaminophen/NSAIDs for more severe cases. Currently, several antispasmodics are undergoing clinical trials, including drotaverine, alverine, pinaverium, otilonium bromide, fenoverine, tiropramide, otilonium bromide, trimebutine, and peppermint oil. Well-designed head-to-head studies are necessary to evaluate current antispasmodics’ safety, efficacy, pharmacokinetic, and pharmacoeconomics profiles. Recent studies have shown that fixed-dose combinations of antispasmodics + NSAIDs or two different antispasmodics can improve patient compliance and synergistically reduce GICP. Therefore, it is recommended that the global availability and accessibility of these products be enhanced.
Systematic ReviewAntispasmodics are the primary treatment for acute gastrointestinal cramping pain, with potential for improved patient compliance and synergistic reduction through fixed-dose combinations.
Full text analysis coming soon...